A clinical trial is set to enter stage three of its research into the autoimmune disease Lupus. The trials, run by Immupharma, are seeing patients from multiple countries take part in the testing of Lupuzor, with the UK and Italy set to join in the third stage of the process in the next few weeks.
The countries that are already taking part in the research are the Czech Republic, France, Germany, Hungary and Poland, along with Mauritius. The newest recruitment drive should see at least 200 people taking part by the end of this year, with the first results due to be released in 2017.
What Is Lupus?
The disease Lupus is a poorly understood condition affecting the immune system. It can cause fatigue, swelling and rashes, with other symptoms including headaches, stomach pain, chest pain, depression, mental health problems and even death.
Lupus can also affect the body’s internal organs, including the heart and liver. It is thought that around five million people around the world are suffering from it. The people most often affected by this disease are women and African-Americans, Asians and Hispanics.
Lupus can take many forms, and the most severe is Systemic Lupus Erythematosus (SLE). This form of the disease is highly debilitating and painful, and it is this severe type of Lupus that the new drug Lupuzor will target.
Lupuzor – The New Drug
This drug has been given the go-ahead by the US Food & Drug Administration (FDA), which speeds up the approval process and shortens the trial periods. The company ImmuPharma, which provides clinical trial services, has also received regulatory approval to complete its protocol assessment. This means the FDA is all set to approve the use of the drug if the trials go to plan.
Clinical trials are necessary for companies to test new drugs in the constant battle against disease, with various services such as http://www.gandlscientific.com/clinical-trial-services helping drugs to be trialled to ensure their absolute safety before becoming available to the public.
Currently, there is one drug approved for use against Lupus, Glaxo Smith Kline’s Benlysta, which generates sales of around $400 million. There are high hopes that Lupuzor will become the drug of choice and usurp the current treatment, which has side effects and is only slightly effective against the disease.